28 related articles for article (PubMed ID: 16969365)
1. Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?".
Zubiaur P; Leeder JS; Abad-Santos F; Gaedigk A
Clin Pharmacol Ther; 2024 Feb; 115(2):184. PubMed ID: 37970726
[No Abstract] [Full Text] [Related]
2. Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms.
Jeong SH; Jang JH; Cho HY; Lee YB
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456605
[TBL] [Abstract][Full Text] [Related]
3. A Life-Threatening Case of Torsemide-Induced Toxic Epidermal Necrolysis Associated With the Treatment of Anasarca.
Reddy S; Aron BK; Stewart J
Cureus; 2022 Mar; 14(3):e22895. PubMed ID: 35399474
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.
Wang X; Yu T; Liao X; Yang C; Han C; Zhu G; Huang K; Yu L; Qin W; Su H; Liu X; Peng T
Cancer Med; 2018 Apr; 7(4):966-980. PubMed ID: 29479826
[TBL] [Abstract][Full Text] [Related]
5. A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials.
de Denus S; Rouleau JL; Mann DL; Huggins GS; Cappola TP; Shah SH; Keleti J; Zada YF; Provost S; Bardhadi A; Phillips MS; Normand V; Mongrain I; Dubé MP
Pharmacogenomics J; 2017 Mar; 17(2):192-200. PubMed ID: 26927285
[TBL] [Abstract][Full Text] [Related]
6. Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution.
Janha RE; Worwui A; Linton KJ; Shaheen SO; Sisay-Joof F; Walton RT
BMC Evol Biol; 2014 Apr; 14():71. PubMed ID: 24690327
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.
Kusama M; Maeda K; Chiba K; Aoyama A; Sugiyama Y
Pharm Res; 2009 Apr; 26(4):822-35. PubMed ID: 19082874
[TBL] [Abstract][Full Text] [Related]
8. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.
Werner D; Werner U; Meybaum A; Schmidt B; Umbreen S; Grosch A; Lestin HG; Graf B; Zolk O; Fromm MF
Clin Pharmacokinet; 2008; 47(5):323-32. PubMed ID: 18399713
[TBL] [Abstract][Full Text] [Related]
9. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
[TBL] [Abstract][Full Text] [Related]
10. Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation at the CYP2C locus and its association with torsemide biotransformation.
Vormfelde SV; Schirmer M; Toliat MR; Meineke I; Kirchheiner J; Nürnberg P; Brockmöller J
Pharmacogenomics J; 2007 Jun; 7(3):200-11. PubMed ID: 16969365
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
14. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.
Suarez-Kurtz G; Genro JP; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Ribeiro-dos-Santos A; Romano-Silva MA; Santana I; Struchiner CJ
Pharmacogenomics J; 2012 Jun; 12(3):267-76. PubMed ID: 21173785
[TBL] [Abstract][Full Text] [Related]
15. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
